Treatment of Leukemia and Lymphoma, Volume 51

1st Edition

Authors: David Scheinberg Joseph Jurcic
Hardcover ISBN: 9780120329526
eBook ISBN: 9780080490403
Imprint: Academic Press
Published Date: 20th September 2004
Page Count: 384
270.00 + applicable tax
165.00 + applicable tax
205.00 + applicable tax
241.00 + applicable tax
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Table of Contents

Kinase Inhibitors in Leukemia State of the Art Treatment of APL Investigational Agents in Myeloid Disorders Methodologic Issues in Investigation of Targeted Therapies in AML Purine Analogues in Leukemia Monoclonal Antibody Therapy in Lymphoid Leukemias Native Antibody and Antibody-Targeted Chemotherapy for Acute Myeloid Leukemia Radioimmunotherapy of Leukemia Immunotoxins and Toxin Constructs in Leukemia/Lymphoma Antibody Therapy of Lymphoma Vaccines in Leukemia Therapeutic Idiotype Vaccines for Non-Hodgkin’s Lymphoma Cytokine Modulation of the Innate Immune System in the Treatment of Leukemia and Lymphoma Donor Lymphocyte Infusions Somatic Cell Engineering and the Immunotherapy of Leukemias and Lymphomas

Description

New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology.

Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers.

The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.

Key Features

  • Provides an up-to-date, state of the art discussion of a rapidly changing field
  • Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells
  • Written by international experts in each of the fields

Readership

Oncologists, hematologists, cancer researchers, pharmacologists, pharmaceutical and biotechonology company employees


Details

No. of pages:
384
Language:
English
Copyright:
© Academic Press 2004
Published:
Imprint:
Academic Press
eBook ISBN:
9780080490403
Hardcover ISBN:
9780120329526

About the Authors

David Scheinberg Author

Affiliations and Expertise

Memorial Sloan Kettering Cancer Center, New York, New York, U.S.A.

Joseph Jurcic Author

Affiliations and Expertise

Memorial Sloan Kettering Cancer Center, New York, New York, U.S.A.